CAR-T Cells for HIV Infection
Phase 1/2
18
about 8.8 years
18–65
2 sites in CA
What this study is about
This trial is testing a new treatment called LVgp120duoCAR-T cells to see if it can help people with HIV. The treatment involves pausing HIV medications temporarily after receiving the CAR-T cells. Participants will be given either a low or high dose of these cells, and some may also receive cyclophosphamide before the infusion.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Analytic Treatment Interruption
- 2.Receive LVgp120duoCAR-T cells, high dose
- 3.Receive LVgp120duoCAR-T cells, low dose
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands)
infusion
Primary: Number of participants reporting a new Grade 3 or greater adverse event that is definitely, probably, or possibly related to study treatment within 1 year of product administration.
Immune, Infectious